Hsbc Holdings PLC Sells 434,971 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Hsbc Holdings PLC lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGXFree Report) by 78.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 119,334 shares of the company’s stock after selling 434,971 shares during the quarter. Hsbc Holdings PLC owned 0.21% of Protagonist Therapeutics worth $2,739,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of PTGX. Principal Financial Group Inc. lifted its position in Protagonist Therapeutics by 7.7% during the third quarter. Principal Financial Group Inc. now owns 14,971 shares of the company’s stock valued at $250,000 after purchasing an additional 1,068 shares during the last quarter. Jump Financial LLC raised its stake in shares of Protagonist Therapeutics by 146.6% in the third quarter. Jump Financial LLC now owns 35,438 shares of the company’s stock valued at $591,000 after acquiring an additional 21,070 shares during the period. Swiss National Bank raised its stake in shares of Protagonist Therapeutics by 2.7% in the third quarter. Swiss National Bank now owns 100,600 shares of the company’s stock valued at $1,678,000 after acquiring an additional 2,600 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Protagonist Therapeutics by 4.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 439,102 shares of the company’s stock valued at $7,324,000 after acquiring an additional 19,492 shares during the period. Finally, Obermeyer Wood Investment Counsel Lllp raised its stake in shares of Protagonist Therapeutics by 9.4% in the third quarter. Obermeyer Wood Investment Counsel Lllp now owns 13,792 shares of the company’s stock valued at $230,000 after acquiring an additional 1,180 shares during the period. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Performance

NASDAQ PTGX opened at $34.02 on Friday. Protagonist Therapeutics, Inc. has a one year low of $13.72 and a one year high of $34.46. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of 13.94 and a beta of 2.12. The company’s 50-day simple moving average is $28.20 and its two-hundred day simple moving average is $26.01.

Protagonist Therapeutics (NASDAQ:PTGXGet Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $3.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.51 by $0.75. The business had revenue of $254.95 million for the quarter, compared to analysts’ expectations of $300.00 million. Equities analysts expect that Protagonist Therapeutics, Inc. will post 1.67 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PTGX has been the topic of several recent analyst reports. JMP Securities increased their target price on shares of Protagonist Therapeutics from $42.00 to $45.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 8th. JPMorgan Chase & Co. increased their target price on shares of Protagonist Therapeutics from $34.00 to $37.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price target on shares of Protagonist Therapeutics in a research note on Thursday, May 9th. Finally, StockNews.com raised shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Get Our Latest Stock Report on Protagonist Therapeutics

Insider Activity

In related news, CEO Dinesh V. Ph D. Patel sold 25,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $28.31, for a total transaction of $707,750.00. Following the completion of the sale, the chief executive officer now directly owns 549,590 shares in the company, valued at approximately $15,558,892.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Asif Ali sold 1,234 shares of the business’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $25.11, for a total transaction of $30,985.74. Following the transaction, the chief financial officer now directly owns 37,163 shares in the company, valued at approximately $933,162.93. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Dinesh V. Ph D. Patel sold 25,000 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $28.31, for a total value of $707,750.00. Following the transaction, the chief executive officer now owns 549,590 shares in the company, valued at $15,558,892.90. The disclosure for this sale can be found here. Company insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Profile

(Free Report)

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.

Recommended Stories

Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.